Created: April 01, 2021 07:31 PM
Pfizer and BioNtech say a new analysis from a Phase 3 study shows their vaccine is still highly effective after several months, including against the South African variant.
The companies say a new analysis included more than 44,000 people. There were 927 symptomatic cases of COVID-19, 77 were in the vaccinated group.
That means the efficacy rate is 91.3%.
It was also highly effective against severe disease, and no serious safety concerns were observed.
The companies also say the vaccine appears to be 100% effective in South Africa, where the South Africa strain is dominant.
Copyright 2021 - WNYT-TV, LLC A Hubbard Broadcasting Company